Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas

被引:57
作者
King, Deanne L.
Stack, Brendan C., Jr.
Spring, Paul M.
Walker, Ronald
Bodenner, Donald L.
机构
[1] Univ Arkansas Med Sci, Dept Otolaryngol Head & Neck Surg, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA
[3] Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA
关键词
D O I
10.1016/j.otohns.2007.02.037
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
OBJECTIVE: Fluorodeoxyglucose (FDG) whole body positron emission tomography (PET) scan may show clinically occult second lesions. Such lesions in the thyroid are increasingly common. There are several recent reports of a high probability of malignancy in these lesions ranging from 14% to 63%. STUDY DESIGN AND SETTING: This is a retrospective review of 15,711 PET scans at a multi-disciplinary thyroid clinic at a tertiary care university medical center. Twenty-two patients were referred with thyroid PET "incidentalomas." The review included 18 FDG-PET scans, ultrasound guided fine needle aspiration biopsies, and thyroid surgery pathology. Aspiration cytology or pathology were the main outcome measures. RESULTS: Three patients had malignancy of the PET-positive thyroid lesions. Papillary thyroid micro carcinomas were detected in four of the specimens that showed a benign pathology of the dominant nodule. CONCLUSION: Our experience shows a 14% malignancy rate for the dominant (imaged) nodule and a total malignancy rate of 32% when the incidental micro carcinomas are included. Both of these rates are significantly lower than results published previously. (c) 2007 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved.
引用
收藏
页码:400 / 404
页数:5
相关论文
共 20 条
[1]  
Carlini M, 2005, J EXP CLIN CANC RES, V24, P231
[2]  
Chen YK, 2005, ANTICANCER RES, V25, P1421
[3]  
Chu QD, 2006, AM SURGEON, V72, P272
[4]   Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography [J].
Cohen, MS ;
Arslan, N ;
Dehdashti, F ;
Doherty, GM ;
Lairmore, TC ;
Brunt, LM ;
Moley, JF .
SURGERY, 2001, 130 (06) :941-946
[5]   Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer:: results of a multicentre study [J].
Diehl, M ;
Risse, JH ;
Brandt-Mainz, K ;
Dietlein, M ;
Bohuslavizki, KH ;
Matheja, P ;
Lange, H ;
Bredow, J ;
Körber, C ;
Grünwald, F .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (11) :1671-1676
[6]  
Helal BO, 2001, J NUCL MED, V42, P1464
[7]  
Ishimori T, 2005, J NUCL MED, V46, P752
[8]   Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects [J].
Kang, KW ;
Kim, SK ;
Kang, HS ;
Lee, ES ;
Sim, JS ;
Lee, IG ;
Jeong, SY ;
Kim, SW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4100-4104
[9]   18F-Fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients:: High prevalence of malignancy [J].
Kim, TY ;
Kim, WB ;
Ryu, JS ;
Gong, G ;
Hong, SJ ;
Shong, YK .
LARYNGOSCOPE, 2005, 115 (06) :1074-1078
[10]   Positron emission tomography in thyroid cancer management [J].
Larson, SM ;
Robbins, R .
SEMINARS IN ROENTGENOLOGY, 2002, 37 (02) :169-174